| Literature DB >> 26352815 |
Alfred L Garfall1, Marcela V Maus, Wei-Ting Hwang, Simon F Lacey, Yolanda D Mahnke, J Joseph Melenhorst, Zhaohui Zheng, Dan T Vogl, Adam D Cohen, Brendan M Weiss, Karen Dengel, Naseem D S Kerr, Adam Bagg, Bruce L Levine, Carl H June, Edward A Stadtmauer.
Abstract
A patient with refractory multiple myeloma received an infusion of CTL019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric antigen receptor, after myeloablative chemotherapy (melphalan, 140 mg per square meter of body-surface area) and autologous stem-cell transplantation. Four years earlier, autologous transplantation with a higher melphalan dose (200 mg per square meter) had induced only a partial, transient response. Autologous transplantation followed by treatment with CTL019 cells led to a complete response with no evidence of progression and no measurable serum or urine monoclonal protein at the most recent evaluation, 12 months after treatment. This response was achieved despite the absence of CD19 expression in 99.95% of the patient's neoplastic plasma cells. (Funded by Novartis and others; ClinicalTrials.gov number, NCT02135406.).Entities:
Mesh：
Substances：
Year: 2015 PMID： 26352815 PMCID： PMC4646711 DOI： 10.1056/NEJMoa1504542
Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245